0.00Open0.03Pre Close0 Volume386 Open Interest80.00Strike Price0.00Turnover714.68%IV0.78%PremiumDec 6, 2024Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.0537Delta0.0822Gamma2647.00Leverage Ratio-33.3372Theta0.0000Rho142.28Eff Leverage0.0002Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet